과제정보
이 논문은 한국연구재단 원자력연구개발사업/방사성동위원소산업 육성 및 고도화 지원사업/수요 맞춤형 동위원소 생산 직접화 및 시설 고도화(NRF-2021M2E7A1079168)과 과학기술정보통신부 한국원자력의학원 연구운영비지원사업(50461-2023)의 지원에 의하여 이루어졌으며 다른 이해관계는 없음을 밝힙니다.
참고문헌
- Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701. https://doi.org/10.1016/j.humpath.2006.11.012
- 최석환.권태균 전립선암 선별검사로서 PSA의 유용성. Korean J Urol Oncol 2013;11:1-5.
- Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. Annu Rev Med 2019;70:479-99. https://doi.org/10.1146/annurev-med-051517-011947
- Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia 2020;22:566-75. https://doi.org/10.1016/j.neo.2020.09.002
- Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA Radioligand Therapy for Prostate Cancer. J Nucl Med 2017;58(8):1196-200. https://doi.org/10.2967/jnumed.117.191023
- Wester HJ, Schottelius M. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Semin Nucl Med 2019;49:302-12. https://doi.org/10.1053/j.semnuclmed.2019.02.008
- Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Prostate Cancer Theranostics: PSMA Targeted Therapy. PET Clin 2021;16:391-6. https://doi.org/10.1016/j.cpet.2021.03.004
- Hennrich U, Eder M. [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel) 2021;14:713.
- FDA Announces Priority Review of 18F-DCFPyL NDA. J Nucl Med 2021;62:21N-22N.
- Lee BS, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim MH, Kim MH, Chi DY, Ahn H, Lee YJ, Lee KC, Lim SM. 18F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer. Prostate 2020;80:1383-93. https://doi.org/10.1002/pros.24062
- Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygun A, Karayel E, Pehlivanoglu H, Alan Selcuk N. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Biodistribution, and Dosimetry. Mol Imaging Radionucl Ther 2017;26:62-8. https://doi.org/10.4274/mirt.08760
- Wrenger R, Juptner M, Marx M, Zhao Y, Zuhayra M, Caliebe A, Osmonov D, Lutzen U. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy. BMC Urol 2022;22:96.
- Schneider CA, Tager P, Hammes J, Fischer T, Drzezga A, Pfister D, Heidenreich A, Schmidt M. Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. Nuklearmedizin 2022;61:25-32. https://doi.org/10.1055/a-1670-9500
- Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel) 2022;15:1292.
- Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, DiMagno SG, Babich JW. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window. J Nucl Med 2019;60:656-63. https://doi.org/10.2967/jnumed.118.221150
- Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, Kiesewetter DO, Jacobson O, Chen X. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug Chem 2018;29:3213-21. https://doi.org/10.1021/acs.bioconjchem.8b00556
- Deberle LM, Tschan VJ, Borgna F, Sozzi-Guo F, Bernhardt P, Schibli R, Muller C. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile. Molecules 2020;25:2542.
- Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, Ceballos M, Meckel M, Benesova M, Umbricht CA, Kluge A, Schibli R, Zhernosekov K, Amaral H, Muller C. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging 2021;48:893-903. https://doi.org/10.1007/s00259-020-05022-3
- Lee BS, Kim MH, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim HS, Kim MH, Kil HS, Han SJ, Lee YJ, Lee KC, Lim SM, Chi DY. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer. Mol Cancer Ther 2021;20:2410-9. https://doi.org/10.1158/1535-7163.MCT-21-0251